Vanqua Bio’s Post

📣For ESMO members: Breaking Science in #BreastCancer. Peter Schmid presents his findings on atezolizumab and sacituzumab govitecan for advanced TNBC. 👉 Explore this video and others from this series on OncologyPRO now. 🔗 https://ow.ly/rci150SmnJm #ESMOBreast24

Interim analysis of atezolizumab + sacituzumab govitecan in Triple Negative #BreastCancer

We are proud to have Christine Miller, PharmD, present a poster presentation at the Alzheimer's Association®'s International Conference. The topic will be Evaluating the safety of anti-amyloid monoclonal antibody infusions in alternative sites of care. We hope to see you there #SpecialtyPharmacy #SimplifyingComplexCare #AAIC24

Today is World Cholangiocarcinoma Day. It's a day to "raise much-needed awareness" of CCA & advocate for a "smoother journey to diagnosis," according to the Global Cholangiocarcinoma Alliance. Don't miss this insightful new article on CCA by our contributor Amanda Brink, DNP, APRN, FNP-BC, AOCNP, who discusses the importance of molecular testing for these patients: https://buff.ly/49gUZKK #WorldCCADay #BeClearOnCCA

ReCode CEO, Dr. Shehnaaz Suliman, shares an important message about our newly initiated Phase 1b clinical trial for RCT2100, a novel therapeutic for people with cystic fibrosis. In this video, Dr. Suliman discusses how patients without current treatment options can get involved and help advance new therapies. Watch below to learn how you can be part of this journey.

By 2025, most doctors and cancer specialists anticipate a rise in the use of biosimilars across various medical conditions. https://ow.ly/qVc150TQ6XZ Samantha Ngan from MMIT provides valuable insights into the current research on biosimilar trends, the timing of payer exclusions of reference products, and key takeaways from the competitive Humira biosimilar market. Click the link in this post for the full article.

By 2025, most doctors and cancer specialists anticipate a rise in the use of biosimilars across various medical conditions. https://ow.ly/Bk4W50TQ85b Samantha Ngan from MMIT provides valuable insights into the current research on biosimilar trends, the timing of payer exclusions of reference products, and key takeaways from the competitive Humira biosimilar market. Click the link in this post for the full article.

"The more we did, the more we saw we were actually changing paradigms." The latest op-ed from Jürgen Eckhardt discusses the revolutionary potential of CAR-T #celltherapy in treating #autoimmunediseases as recent studies have shown remarkable results for patients with severe autoimmune conditions like #lupus. One inspiring case involved a young woman with a critical case of lupus who had no other treatment options. After receiving CAR T-cell therapy, she not only survived but thrived, passing the 1000-day mark of remission and reclaiming her life. Such stories underscore the transformative potential of CAR T-cell therapy, which was initially developed for blood cancers but now shows promise for autoimmune diseases. Our portfolio company, Capstan Therapeutics, is pioneering in vivo CAR-T therapies, which aim to simplify and scale this potentially revolutionary treatment. By leveraging #mRNA technology, Capstan's approach could enable the patient's body to produce CAR T cells directly, making the treatment more accessible and efficient. Read more on this exciting journey towards better, more effective treatments for autoimmune diseases and beyond: https://lnkd.in/gbVtSEGM

Clinical trials are essential for discovering new treatments for life-threatening conditions such as cancer and heart disease. 🗝 These trials pave the way for medical advancements that offer hope to millions of people worldwide. By participating, you play a critical role in shaping the future of healthcare and unlocking life-saving solutions. Each trial brings us closer to better treatments and improved outcomes for those in need. 🩺 Medcare Pharma: Your Way to Cure Contact us: ☎️ | 1-866-4-MEDICINE 📧 | info@medcarepharma.care 🌐 | https://lnkd.in/gA9pPUVR #MedicalResearch #HopeForTheFuture #clinicaltrial #clinicalresearch #medicalresearch #clinicalstudies #clinicalstudy #healthcare #medcarepharma #researchstudies

🎙️ Brian Rini, MD, FASCO, and Tom Powles, MBBS, MRCP, MD, of the Uromigos spoke with Matt Galsky, MD, about the #OS signal data from #CheckMate274, which analyzed the use of #adjuvant #nivolumab in patients with #MIBC. 👂 Listen Here: